
Sign up to save your podcasts
Or


Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.
By ReachMD4.5
22 ratings
Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.

39 Listeners

10 Listeners

59 Listeners

1,145 Listeners

195 Listeners

45 Listeners

7 Listeners